Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer  by Porter, Charlene et al.
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Antibodies  to tumor  necrosis  factor  (anti-TNF)  are  used  to treat  inﬂammatory  diseases,  which  often  affect
women  of childbearing  age.  The  active  transfer  of  these  antibodies  across  the  placenta  by binding  of  the
Fc-region  to the  neonatal  Fc  receptor  (FcRn)  may  result  in  adverse  fetal or neonatal  effects.  In  contrast
to  other  anti-TNFs,  certolizumab  pegol  lacks  an  Fc-region.  The  objective  of this  study  was  to  determine
whether  the  structure  of  certolizumab  pegol  limits  active  placental  transfer.
Binding  afﬁnities  of  certolizumab  pegol,  inﬂiximab,  adalimumab  and  etanercept  to  human  FcRn  and
FcRn-mediated  transcytosis  were  determined  using  in  vitro  assays.  Human  placentas  were  perfused  ex
vivo  to measure  transfer  of  certolizumab  pegol  and  positive  control  anti-D  IgG  from  the  maternal  to fetal
circulation.
FcRn binding  afﬁnity  (KD) was  132  nM,  225  nM  and  1500  nM  for  inﬂiximab,  adalimumab  and  etan-
ercept,  respectively.  There  was  no  measurable  certolizumab  pegol  binding  afﬁnity,  similar  to  that  of
the negative  control.  FcRn-mediated  transcytosis  across  a cell  layer  (mean  ± SD;  n  = 3)  was 249.6  ± 25.0
(inﬂiximab),  159.0  ±  20.2  (adalimumab)  and  81.3 ± 13.1 ng/mL  (etanercept).  Certolizumab  pegol  tran-
scytosis  (3.2  ±  3.4  ng/mL)  was  less  than  the  negative  control  antibody  (5.9  ± 4.6 ng/mL).  No  measurable
transfer  of certolizumab  pegol  from  the  maternal  to the  fetal  circulation  was  observed  in  5 out  of  6
placentas  that  demonstrated  positive-control  IgG  transport  in  the  ex vivo  perfusion  model.
Together  these  results  support  the  hypothesis  that the  unique  structure  of certolizumab  pegol  limits
its  transfer  through  the  placenta  to the  fetus  and  may  be  responsible  for  previously  reported  differences
in  transfer  of  other  anti-TNFs  from  mother  to fetus.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Tumor necrosis factor (TNF) alpha is an important cytokine in a
umber of diseases with a signiﬁcant inﬂammatory component,
ncluding Crohn’s disease (CD), rheumatoid arthritis (RA), axial
pondyloarthritis (axSpA) and psoriatic arthritis (PsA) (Wiedmann
t al., 2009). Biologic anti-TNF medications, including inﬂiximab
∗ Corresponding author at: UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK.
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ttp://dx.doi.org/10.1016/j.jri.2016.04.284
165-0378/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(IFX), adalimumab (ADA), etanercept (ETA), certolizumab pegol
(CZP) and golimumab are frequently used for the treatment of such
diseases.
Inﬂammatory diseases often affect women of reproductive age,
and the risk of adverse pregnancy outcomes correlates with disease
activity (Morales et al., 2000; Bush et al., 2004; Norgard et al., 2007;
De Man  et al., 2009). There is a need for adequate disease control
during pregnancy (Ostensen and Forger, 2009; Mahadevan et al.,
2011; Ng and Mahadevan, 2013), which has raised concern over the
safety of biologic agents for pregnant and breast-feeding women.
Current evidence from human studies suggests these agents do not
pose a signiﬁcant clinical risk to conception or early pregnancy (Ali
et al., 2010; Fischer-Betz and Schneider, 2010, Mahadevan et al.,
2012) or increase the risk of adverse outcomes (Raja et al., 2012;
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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archioni and Lichtenstein, 2013). However, these reports advise
o discontinue treatment in the third trimester to limit placental
ransfer; while such statements are cautionary through a lack of
nvestigative knowledge, this conclusion is reﬂected in a number
f treatment guidelines (Ostensen and Forger, 2009; Mahadevan
t al., 2011; Ng and Mahadevan, 2013; Flint et al., 2016).
CZP has a unique structure compared to the other approved
nti-TNF therapies, which may  inﬂuence fetal exposure during
regnancy. It is a monovalent Fab’ fragment of a humanized
onoclonal attached to a polyethylene glycol (PEG) chain, which
onsequently lacks an Fc-region (Fig. 1) (Bourne et al., 2008; Rivkin,
009). In contrast, the monoclonal antibodies IFX and ADA, and the
NF receptor-IgG Fc fusion protein ETA all possess an IgG1 Fc-region
Fig. 1). Binding of the IgG Fc-region to the neonatal Fc receptor
FcRn) plays an important role in regulating IgG homeostasis by
rotecting antibodies from degradation (Junghans and Anderson,
996; Ghetie et al., 1997). In contrast, the plasma half-life of CZP is
rolonged by the presence of a PEG moiety (Nesbitt et al., 2007). The
gG Fc-domain is also involved in the active transport of antibod-
es across the placenta, from maternal to fetal circulation, which
s mediated by binding to FcRn (Roberts et al., 1990; Simister and
tory, 1997; Saji et al., 1999). Thus, the presence or absence of an
c-region would be expected to inﬂuence binding of biologics to
cRn and affect their active transport across the placenta.
The objective of this study was to determine whether the unique
tructure of CZP limits its active placental transfer.
. Materials and methods
.1. Therapeutic and control reagents
Inﬂiximab (Tanabe Pharmaceutical, Osaka, Japan), adalimumab
Abbvie, Baar, Switzerland) and etanercept (Takeda Pharmaceuti-
al, Osaka, Japan) were all purchased from European distributors.
ZP, a control non-PEGylated CZP Fab’ (control used in the FcRn
inding assay) and P146 antibody (negative control used in the
cRn transcytosis assay) were supplied by UCB Pharma. The P146
egative control antibody was a whole IgG, with speciﬁcity to
apten 2,4-dinitrophenol (James and Tawﬁk, 2003), modiﬁed to
revent FcRn binding by mutation of three residues (I253A, H310A,
435A) within the Fc region identiﬁed as necessary for bind-
ng to FcRn (Roopenian and Akilesh, 2007). A polyclonal human
nti-D IgG (supplied under agreement by CSL Behring), known to
ndergo materno-fetal transfer in the ex vivo placental transfer
odel (Urbaniak et al., 1997), was used as a positive control.
.2. In vitro human FcRn binding assay and quantiﬁcation
A label-free surface plasmon resonance-based assay (BiacoreTM,
E Healthcare UK) was used to determine the kinetics (on and off
ates) and afﬁnity (binding strength) of the interaction between
he anti-TNFs and human FcRn. Binding of a non-PEGylated CZP
ab’ was also assessed to determine whether PEGylation affected
inding of the CZP Fab’ to FcRn.
Human FcRn extracellular domain (IgG Fc-binding domain) was
xpressed in CHO cells transiently transfected with human FcRn
lpha chain and beta 2-microglobulin (B2M).  The FcRn-B2M het-
rodimer was prepared by afﬁnity chromatography on a column of
uman IgG. The human FcRn extracellular domain was  immobilized
n the test chip by amine coupling to a level of 267 RU (response
nits). Samples were passed over the FcRn-coated chip (30 L/min)
n running buffer (0.02 M phosphate/0.15 M sodium chloride, pH
.0/0.05% v/v polysorbate P20) for 5 min  at a range of concentra-
ions (0 nM,  21 nM,  42 nM,  84 nM,  168 nM,  335 nM and 670 nM)
o determine the binding on-rate; pH 6 buffer was  used to allowe Immunology 116 (2016) 7–12
optimum binding. The FcRn binding model represents the intra-
cellular environment and endosomal internalisation of IgG bound
to the extracelluar FcR domain, which is known to be optimal at
pH 6 and inactive at physiological pH (Chaudhury et al., 2003). The
off-rate was followed for a further 5 min  by running buffer alone
over the chip. A zero control sensorgram was  run every second
cycle in order to account for baseline drift and bulk buffer effects;
a total of 30 such controls were tested and all produced overlying
sensorgrams close to baseline. The chip surface was  regenerated
between cycles using 3 × 80 s pulses of regeneration buffer (200 nM
sodium chloride/100 mM  TRIS, pH 8.0). Data were normalized by
subtracting blank ﬂow cell data and mean zero control cycle data.
The average dissociation constant (KD) for each compound was  cal-
culated from a global ﬁt of association and dissociation kinetics
measured over six concentrations (12 replicate experiments).
2.3. In vitro human FcRn transcytosis assay and quantiﬁcation
Madin Darby Canine Kidney (MDCK-II) cells transfected with
human FcRn and B2M (Claypool et al., 2002) were cultured in min-
imal essential medium (MEM)  supplemented with 10% v/v fetal
bovine serum (FBS), 2 mM l-glutamine, 1% w/v non-essential amino
acids, and 1% w/v sodium pyruvate (Invitrogen) at 37 ◦C/5% CO2.
The cells were cultured for 3 days in a 24-well transwell plate (BD
Falcon), until an intact monolayer was  formed, conﬁrmed by mea-
suring trans-epithelial resistances, which were at least 150 cm2
(Claypool et al., 2002).
The cells were washed with pH 7.2 Hanks’ balanced salt solu-
tion (HBSS; Invitrogen), and biotinylated anti-TNFs (biotinylated
using a kit from Roche) were added to the apical surface in HBSS
pH 5.9 with 1% v/v bovine serum albumin (BSA) (pH adjusted with
10 mM 4-morpholineethanesulfonic acid [MES]) at 10 g/mL. HBSS
pH 7.2 with 1% v/v BSA (buffered with 10 mM HEPES) was added to
the basolateral side. The use of 1% v/v BSA in the apical and baso-
lateral surfaces was  consistent with the methods described in the
literature (Claypool et al., 2004). Anti-TNF concentration was quan-
tiﬁed in the basolateral supernatant after 4 h’ incubation at 37 ◦C.
The 4-h sampling time was optimal for the assay to establish the
maximum signal from the transcytosis assay without interfering
with the integrity of the monolayer and was validated for spe-
ciﬁc FcRn-dependent transport with the P146 control (FcRn binding
abolished) antibody in all assays. The amount of each anti-TNF
transcytosed was  measured using a meso scale discovery (MSD)
electrochemiluminescent assay. The biotinylated anti-TNFs were
captured on an MSD  plate with an anti-human IgG antibody (Jack-
son Labs), then detected with a streptavidin sulpho-tag reagent
(MSD). The electrochemiluminescent signal was  determined using
an MSD  Sector Imager 6000 plate reader. Levels of each test anti-
TNF were determined by comparison to a standard curve for each
corresponding anti-TNF tested. Average (arithmetic mean) amount
of anti-TNF transcytosed and the standard deviation (SD), were
calculated for each anti-TNF from 3 replicate experiments.
2.4. Ex vivo placental transfer model
The collection of human placentas was subject to North
of Scotland Research (NORES) Ethical Committee (Ethics Refer-
ence 09/S0801/006) and National Health Service (NHS) Grampian
Research and Development Ofﬁce approval and was  audited (June
2010).
Freshly delivered placentas from elective caesarean sections
were used after obtaining patients’ written informed consent.
Placental perfusion was  carried out according to published meth-
ods (Duncan et al., 1995), previously validated for assessing IgG
materno-fetal antibody transport (Armstrong-Fisher et al., 1997).
Brieﬂy, a placental lobule was  cannulated from fetal and maternal
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Fig. 1. Diagrammatic representations of the comparative structures of inﬂiximab, adalimumab, etanercept and certolizumab pegol (CZP).
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iagram adapted from Weir et al. (2006).
spects, circulations were established, and the lobule was  perfused
or ≥30 min  under ‘open circuit’ conditions at 37 ◦C to wash out
rythrocytes and protein with RPMI-1640 media (Invitrogen) (fetal
ow rate: ∼6 mL/min; maternal ﬂow rate: ∼20 mL/min). Isolated
obules weighed, on average, 39.0 g; placental viability was  con-
rmed by oxygen consumption. The ‘fetal’ circulation contained
5% N2 and 5% CO2, whereas the ‘maternal’ circulation contained
5% O2 and 5% CO2. Once circulation was established, the circuit
as closed (ie. both circuits were in closed circuit perfusion). Sub-
equently, CZP (200 g/mL) and positive control polyclonal anti-D
gG (30 g/mL) were added simultaneously to 200 mL  of perfusate
RPMI-1640 media, dextran and antibiotics) in the maternal cir-
ulation. The fetal perfusate consisted of 200 mL  of perfusate with
.363 g BSA added to provide what would be the normal protein
ontent in the fetal placental circulation. Experiments were con-
ucted for at least 4 h, with total perfusion time dependent on
aintenance of tissue integrity, allowing re-circulation of anti-
odies through the placenta. The integrity of placental tissue was
hecked throughout perfusion by visual inspection, measurement
f maternal and fetal reservoir volumes, and overall fetal return
mL/h × number of hours of perfusion, adjusted for fetal volume
oss and expressed as a percentage), with a range of 84–97% fetal
eturn.
Three 1 mL  perfusate samples were collected from the maternal
nd fetal reservoirs at hourly intervals for up to 6 h. Samples were
entrifuged (15,521g, 10 min) to remove cellular debris and stored
t −40 ◦C. Triplicate samples at each time point were used for dif-
erent measurements (e.g. anti-D or CZP quantiﬁcation) and were
ot pooled for analysis.
.5. Ex vivo placental transfer model: quantiﬁcation of CZP
CZP in ex vivo placental perfusates was determined using
n enzyme-linked immunosorbent assay (ELISA) (developed by
CB Pharma). The ELISA method lower limit of quantiﬁcation
as 0.41 g CZP/mL perfusate. Perfusate samples were incubated
or 1 h with immobilized human TNF alpha on 96-well plates.
fter washing, peroxidase-conjugated goat anti-human kappa light
hain (which binds to CZP; MP  Biomedicals) was added, and the
lates were incubated for 30 min  at room temperature (19–22 ◦C).
etramethylbenzidine substrate solution was added after washing
nd the reaction stopped after 15 min. Absorbance was measured
t 450 nm (with subtraction at 630 nm to eliminate backgroundrising of a monovalent Fab’ fragment of a humanized monoclonal attached to a
absorbance). Data were analyzed using Watson LIMS version 7.2
software (Thermo Scientiﬁc).
2.6. Ex vivo placental transfer model: quantiﬁcation of anti-D IgG
Anti-D IgG concentrations were determined using a calibrated
ﬂow cytometric immunoassay with rhesus blood group D antigen
(RhD)-positive red blood cells (RBCs). The lower limit of quantiﬁ-
cation of anti-D IgG was 0.008 g/mL.
RBCs expressing RhD antigen were diluted to give a ﬁnal con-
centration of 100 × 106 cells/mL. A standard curve was prepared
using doubling dilutions of stock anti-D IgG between 1000 ng/mL
and 0.06 ng/mL. Aliquots of RBCs were added to the respective anti-
D IgG dilutions and incubated for 1 h at 37 ◦C. Cells were washed
three times in phosphate buffered saline (PBS), then incubated in
the dark for 20 min  with a FITC conjugated-Fab’ fragment of goat
anti-human IgG (Fab′-FITC, ICN Pharmaceuticals/Valeant Pharma-
ceuticals) secondary antibody. Finally, RBCs were washed three
times and then resuspended in PBS for anti-D IgG quantiﬁcation by
ﬂow cytometry (Epics XL-MCL ﬂow cytometer; Beckman Coulter).
Mean channel ﬂuorescence (MCF) values for each dilution were
obtained, and a standard curve was plotted. Placental perfusion
samples were processed as described above; fetal samples were
used undiluted and maternal samples were diluted 1/100 in PBS.
MCF  values for all samples at each time point of closed-circuit per-
fusion were obtained. Concentration of anti-D IgG in each sample
was calculated using the standard curve equation (y = mx  + c). Final
anti-D IgG concentrations were calculated and corrected for their
dilution factor.
2.7. Calculation of ex-vivo placental transfer
Materno-fetal transfer of CZP and anti-D IgG was calculated as
the transfer fraction (Tf%): Tf% = [IgG]f × 100/[IgG]m, where [IgG]f
and [IgG]m = concentration of total anti-D IgG/CZP in the fetal (f)
and maternal (m)  circuits, respectively.
3. Results3.1. In vitro binding of anti-TNFs to human FcRn
High binding afﬁnities for FcRn were found with the mono-
clonal antibodies IFX and ADA (Table 1; Fig. 2A and B), which were
10 C. Porter et al. / Journal of Reproductive Immunology 116 (2016) 7–12
Table 1
Binding afﬁnity of anti-TNFs for human FcRn extracellular domain at pH 6, deter-
mined by a label-free surface plasmon resonance-based assay (BiacoreTM).
Anti-TNF Afﬁnity (KD), mean ± SDa
Inﬂiximab (IFX) 132 ± 23 nM
Adalimumab (ADA) 225 ± 33 nM
Etanercept (ETA) 1500 ± 323 nM
Certolizumab pegol (CZP) No binding
Non-PEGylated CZP Fab’ No binding
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pissociation constant (KD) was calculated from the monovalent binding kinetics
easured at 6 concentrations.
a 12 replicate experiments.
ithin the range of values reported from similar assays (Gurbaxani
t al., 2013). In comparison, the binding afﬁnity of ETA to FcRn was
pproximately 5–10-fold lower than that observed for the mono-
lonal antibodies (Table 1; Fig. 2C). This is similar to the dissociation
onstant previously reported (Suzuki et al., 2010). In contrast to the
ther anti-TNFs tested, CZP (PEGylated and non-PEGylated) did not
ind to the FcRn with any measurable afﬁnity (Table 1; Fig. 2D and
).
.2. In vitro human FcRn-mediated transcytosis of anti-TNFs
FcRn-mediated transcytosis of the monoclonal antibodies was
ound to be greater than that for the other types of anti-TNFs tested
Fig. 3). ETA transcytosis was less than that of both ADA and IFX,
nd the level of CZP transcytosis was signiﬁcantly lower than that
bserved for all the other anti-TNFs tested (Fig. 3). The negative
ontrol antibody (P146) also demonstrated a low level of transfer
Fig. 3), similar to that observed for CZP.
.3. Ex vivo placental transfer of CZP
Placental perfusion was validated for transport capability by
emonstrating steady-state, materno-fetal transfer of the positive
ontrol anti-D IgG. The anticipated perfusion success rate is approx-
mately 40%, and 11 out of 18 placentas achieved closed-circuit
erfusion for ≥4 h. Of these perfusions, 6 showed signiﬁcant anti-
 IgG transport (Table 2), and the transfer fraction average was
.41 ± 0.24% (n = 6; mean ± SD); data are shown for the sample
aken at the last time point assessed when anti-D IgG transfer was
ighest. Both the rate and total amount of anti-D IgG transport were
ypical (Duncan et al., 1995), despite the presence of CZP, indicat-
ng no apparent inhibitory effect of CZP on the placental transfer of
gG.
Mean duration of closed circuit perfusion was  5 h, and the
ongest perfusion duration in a single placenta was 13 h (Placenta
, Table 2). There were no unusual ﬁndings upon visual inspection
able 2
x vivo placental transfer of anti-D IgG and certolizumab pegol (CZP) from maternal
o fetal circulation (data shown are from the sample taken at the last time point
ssessed when anti-D IgG transfer was highest, which was  the ﬁnal perfused hour
n  all cases).
Placenta number Perfusion time
(hours)
Anti-D IgG
transport (%)
CZP transport (%)
1 6 0.002 <0.21a
2 13 0.26 <0.21a
3 4 0.06 <0.21a
4b 4 0.53 0.46
5  5 0.46 <0.21a
6 5 0.74 <0.21a
a Below lower limit of quantiﬁcation.
b This placenta showed evidence of breakdown of the fetal capillary bed and non-
peciﬁc leakage (leakage to another area of the placenta other than the lobule being
erfused) from the fetal to the maternal circuit.
Fig. 2. Representative kinetics of human FcRn binding by anti-TNFs.
High binding afﬁnities for FcRn were found with the monoclonal antibodies IFX and
ADA; the binding afﬁnity of ETA to FcRn was approximately 5–10-fold lower than
that observed for the monoclonal antibodies, whereas CZP (PEGylated and non-
PEGylated) did not bind to the FcRn with any measurable afﬁnity. Abbreviations:
CZP, certolizumab pegol; ADA, adalimumab; IFX, inﬂiximab; ETA, etanercept.
of the placental architecture in Placenta 2 compared with the other
placentae. The concentration of CZP in maternal circuits remained
between 40 g/mL and 200 g/mL (the starting concentration)
during perfusion, somewhat higher than normal CZP plasma con-
centrations in patients treated in the clinic (FDA, 2014). The pH of
C. Porter et al. / Journal of Reproductiv
Fig. 3. In vitro transcytosis of anti-TNFs across a MDCK II cell monolayer engineered
to express human FcRn and B2M (ng/mL over period of 4 h; mean ± SD, n = 3).
ETA transcytosis was  less than that of both ADA and IFX, and the level of CZP tran-
scytosis was  signiﬁcantly lower than that observed for all the other anti-TNFs tested.
The negative control antibody (P146) also demonstrated a low level of transfer, sim-
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bbreviations: P146, negative control antibody; CZP, certolizumab pegol; ADA, adal-
mumab; IFX, inﬂiximab; ETA, etanercept.
oth fetal and maternal arterial supply and venous returns were
easured at the end of perfusion and, in the 6 placentas, ranged
rom: pH 6.8–7.1 in the fetal arterial supply; pH 6.7–7.5 in the
etal venous return; pH 7.3–7.8 in the maternal arterial supply, and
H 7.2–7.6 in the maternal venous return. Fetal loss ranged from
.22–0.73 mL/min. In 5 of the 6 placentas that demonstrated anti-D
gG transfer, the level of CZP in the fetal perfusate was  below the
ower limit of quantiﬁcation by ELISA for the entire duration of per-
usion (Table 2). The remaining placenta demonstrated measurable
ZP materno-fetal transfer (Table 2), however, visual inspection
f placenta number 4 suggested breakdown of the fetal capillary
ed, which was supported by observed excessive loss from the fetal
eservoir.
. Discussion
Given the key role played by FcRn binding of IgG Fc-region in
he active placental transport of antibodies (Roberts et al., 1990;
imister and Story, 1997; Saji et al., 1999), we compared FcRn bind-
ng for a variety of anti-TNFs. The anti-TNFs tested fell into three
road structural categories: monoclonal antibodies (ADA and IFX),
 TNF receptor-IgG Fc fusion protein (ETA) and a monoclonal anti-
ody Fab’ fragment (CZP). The monoclonal antibodies IFX and ADA
ere found to have high afﬁnity for FcRn, which is unsurprising,
iven their intact Fc-region. The TNF receptor-IgG Fc fusion pro-
ein ETA, which also has an Fc-region, exhibited a lower afﬁnity
or FcRn compared to the monoclonal antibodies, although bind-
ng was still measurable. This reduced afﬁnity for FcRn has been
eported previously, and may  be due to fusion of the TNF recep-
or to the Fc-region either altering the conformation of the binding
egion or causing steric hindrance, which in turn interferes with
cRn binding (Suzuki et al., 2010). In contrast, CZP, which lacks an
c-region, did not bind FcRn with any measurable afﬁnity. As CZP is
lso PEGylated, in order to prolong plasma half-life (Bourne et al.,
008), we conﬁrmed that the PEGylation cannot be responsible for
he lack of FcRn binding, given the non-PEGylated CZP Fab’ also
emonstrated no measureable FcRn binding.
The hypothesis that the inability of CZP to bind FcRn conse-
uently leads to a lack of active drug transport was  tested in vitro,
here a direct relationship was observed between FcRn bind-
ng afﬁnity and the amount of anti-TNF actively transported. IFX
nd ADA, which possess high binding afﬁnity for FcRn, and ETA,
hich has lower, but measurable afﬁnity for FcRn, all demonstratede Immunology 116 (2016) 7–12 11
FcRn-mediated transcytosis. In contrast, transcytosis of CZP was
substantially lower and comparable to transport of a negative con-
trol antibody (P146), which was  modiﬁed to prevent FcRn binding.
Given that neither the negative control antibody nor CZP bind
FcRn, the levels of CZP detected in this assay are possibly due to a
low level of non-speciﬁc leakage across the cell layer, rather than
active receptor-mediated transport. These results also support the
hypothesis that the low levels of CZP placental transfer reported in
patients (Mahadevan et al., 2013) may  be due to the lack of binding
to FcRn preventing active transport. This is in contrast to IFX and
ADA, which demonstrated relatively high binding afﬁnity to FcRn,
and were previously reported to undergo materno-fetal transfer
(Mahadevan et al., 2013).
We also directly tested materno-fetal transfer of CZP in an ex
vivo human placental transfer system, and results indicate very
low levels of CZP transfer from maternal to fetal circulation. Since
this was expected, the concentration of CZP added to the mater-
nal circulation was much higher than would be observed in clinical
use to facilitate detection. As a result, CZP concentrations in the
maternal circulation were between 40 and 200 g/mL (the start-
ing concentration) during perfusion, whereas mean peak plasma
concentrations reported in RA patients receiving CZP according
to prescribing information (i.e. loading dose of 400 mg subcuta-
neously at weeks 0, 2 and 4, followed by 200 mg  every other week)
are between 43 g/mL and 49 g/mL (FDA, 2014). In the placentas
where CZP transfer was  detected, excessive loss of the fetal reser-
voir and evidence of breakdown of the fetal capillary bed were
noted, suggesting non-speciﬁc leakage into the maternal circuit.
However, the level of materno-fetal CZP transfer still remained
below that seen with the anti-D IgG control. We  hypothesize that
the inability of CZP to bind FcRn could account for the observed
differences between the placental transfer of the anti-D IgG control
and CZP.
This hypothesis also offers an explanation for reported low lev-
els of in utero CZP placental transfer, compared to other anti-TNFs
(Mahadevan et al., 2013). In this clinical study, low CZP serum
concentrations ( < 2 g/mL) were found in both infant and cord
blood (median ratio of cord-to-maternal CZP level was  3.9% [range
1.5–24%]) at birth after CZP treatment during pregnancy to con-
trol inﬂammatory bowel disease. In comparison, concentrations
of both IFX and ADA were signiﬁcantly higher in both cord blood
(160% and 153% of maternal plasma concentration for IFX and ADA,
respectively) and infants at birth. These results reﬂect similari-
ties to the in vitro transcytosis and ex vivo placental transfer data
described here and correlate with FcRn binding afﬁnity. Together,
these results suggest that a lack of FcRn binding prevents active
transport of CZP, which leads to minimal placental transfer.
Given its reported minimal placental transfer, it has been rec-
ommended that CZP may  be continued throughout pregnancy (Ng
and Mahadevan, 2013). However, all use of anti-TNFs during preg-
nancy is currently not approved, and as clinical data are limited,
uncertainty persists. The results from the present study support
the conclusion that CZP does have a low propensity for materno-
fetal transfer, perhaps the lowest placental transfer rate of current
anti-TNFs; thereby providing an explanation for previous clinical
observations (Mahadevan et al., 2013). Clearly, additional clinical
data are required to fully assess the safety and tolerability of anti-
TNFs in pregnancy. However, the ﬁndings of this study suggest the
impact on the fetus is lessened by the unique structure of CZP and
resultant extremely low placental transfer.Acknowledgements
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